Arvinas Inc (ARVN)

Apr 23, 2025, 10:44 AM EDT - 2 days ago

Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 21, 2025, 7:00 AM EDT - 4 days ago

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at 2025 American Association for Cancer Research® (AACR) Annual Meeting

Apr 4, 2025, 3:38 PM EDT - 21 days ago

Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study

Apr 4, 2025, 7:00 AM EDT - 21 days ago

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation

Mar 27, 2025, 7:00 AM EDT - 4 weeks ago

Arvinas Announces Oral Presentation at 2025 International Conference on Alzheimer's & Parkinson's Diseases

Mar 26, 2025, 7:06 AM EDT - 4 weeks ago

Top 3 Health Care Stocks That Are Set To Fly This Month

IOVA SLP

Mar 11, 2025, 12:30 PM EDT - 6 weeks ago

Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial

PFE

Mar 11, 2025, 6:58 AM EDT - 6 weeks ago

Arvinas-Pfizer's breast cancer treatment meets main goal in late-stage study

PFE

Mar 11, 2025, 6:45 AM EDT - 6 weeks ago

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

PFE

Mar 4, 2025, 4:05 PM EST - 7 weeks ago

Arvinas to Participate in Upcoming Investor Conferences

Feb 12, 2025, 12:04 PM EST - 2 months ago

These Analysts Revise Their Forecasts On Arvinas After Q4 Results

Feb 11, 2025, 3:22 PM EST - 2 months ago

Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 7:00 AM EST - 2 months ago

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 3, 2025, 7:00 AM EST - 2 months ago

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

Jan 10, 2025, 7:00 AM EST - 3 months ago

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

Dec 10, 2024, 9:05 AM EST - 4 months ago

Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium

Dec 4, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 5 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 2, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Shareholders to Inquire about Securities Investigation

Dec 1, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Shareholders to Connect

Nov 29, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Arvinas, Inc. (ARVN) And Encourages Investors to Connect

Nov 28, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Stockholders to Inquire about Securities Investigation

Nov 27, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Investors to Learn More About the Investigation

Nov 27, 2024, 7:00 AM EST - 5 months ago

Arvinas to Present at Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 10:00 AM EST - 5 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 25, 2024, 5:35 PM EST - 5 months ago

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium

Nov 25, 2024, 10:00 AM EST - 5 months ago

Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 24, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Stockholders to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Arvinas, Inc. (ARVN) Investors to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Investors to Reach Out

Nov 20, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arvinas, Inc. (ARVN) And Encourages Stockholders to Reach Out

Oct 30, 2024, 3:43 PM EDT - 6 months ago

Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 7:00 AM EDT - 6 months ago

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 22, 2024, 4:05 PM EDT - 6 months ago

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

Oct 21, 2024, 7:00 AM EDT - 6 months ago

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Jul 19, 2024, 2:15 PM EDT - 10 months ago

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

CI HUBS FLNG GRFS IGR INTR KREF

Jun 24, 2024, 4:37 PM EDT - 10 months ago

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

Jun 21, 2024, 7:00 AM EDT - 11 months ago

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

Jun 17, 2024, 7:00 AM EDT - 11 months ago

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.